To further determine the role of AKT and ERK signals in Kyn-associated tumor progression, AKT inhibitor MK-2206 and ERK1/2 inhibitor Rav to treat lung cancer cells cultured with a medium containing Kyn was used. Here, MAPK3 is linked to neoplasm.